IL10 and myeloid sarcoma: Although the precise molecular mechanism that determines the development from PALs to inflammatory demyelinating lesions is not clear in MS or its animal models, it has been proposed that production of anti-inflammatory cytokines, such as interleukin (IL)-10, from microglia would lead to lesion resolution.